Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Earnest Partners LLC

Earnest Partners LLC lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 982,154 shares of the medical research company’s stock after acquiring an additional 735 shares during the period. Earnest Partners LLC’s holdings in Charles River Laboratories International were worth $181,306,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Fiduciary Financial Group LLC raised its holdings in shares of Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after purchasing an additional 63 shares during the period. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the period. Cornerstone Investment Partners LLC lifted its holdings in Charles River Laboratories International by 3.7% in the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock worth $358,000 after acquiring an additional 69 shares during the last quarter. Metis Global Partners LLC boosted its stake in Charles River Laboratories International by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company’s stock valued at $318,000 after acquiring an additional 72 shares during the period. Finally, Two Sigma Securities LLC grew its holdings in shares of Charles River Laboratories International by 4.3% during the fourth quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company’s stock valued at $366,000 after purchasing an additional 81 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Trading Down 0.9 %

Shares of Charles River Laboratories International stock opened at $114.71 on Friday. The business has a fifty day simple moving average of $146.73 and a 200-day simple moving average of $171.12. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The firm has a market cap of $5.63 billion, a price-to-earnings ratio of 764.73, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.46 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the subject of a number of analyst reports. Barclays reduced their price objective on Charles River Laboratories International from $160.00 to $145.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. JPMorgan Chase & Co. lowered their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price target for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective for the company in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $182.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).